Analyzing heart damage after stroke using a blood biomarker
Stroke-induced Myocardial Dysfunction: Role of GDF-15 (SMOG-15) Clinical Work Package
This study is testing if a blood marker called GDF-15 can help us understand heart damage in people who have had a stroke.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 130 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire Dijon Academic / other |
| Locations | 1 site (Dijon) |
| Trial ID | NCT05683873 on ClinicalTrials.gov |
What this trial studies
This study investigates the relationship between the blood biomarker GDF-15 and myocardial dysfunction following an ischemic stroke. Conducted at the Dijon University Hospital in France, it involves a series of interventional assessments including blood tests, electrocardiograms, and echocardiograms during hospitalization and follow-up. A total of 130 stroke patients will participate, with evaluations occurring shortly after the stroke and again 4 to 6 months later. The goal is to better understand how GDF-15 levels correlate with heart damage in stroke patients.
Who should consider this trial
Good fit: Ideal candidates are adults experiencing their first acute ischemic stroke within 24 hours of symptom onset.
Not a fit: Patients with a history of symptomatic stroke or pre-existing heart conditions will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of heart complications in stroke patients.
How similar studies have performed: While the specific approach of using GDF-15 in this context may be novel, similar studies have explored biomarkers in relation to heart damage post-stroke with varying degrees of success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult with acute symptomatic cerebral infarction documented by brain imaging on admission (cerebral angioscan or cerebral MRI) * Whose first symptoms appeared within 24 hours before inclusion * Whose consent to participate in this study was obtained from the patient or a close relative. Exclusion Criteria: * Person with a history of symptomatic stroke, either ischemic or hemorrhagic * Anyone with a history of heart disease including: atrial fibrillation or flutter (known or discovered on admission), chronic heart failure, pacemaker, defibrillator, or other cardiac devices * Person with acute heart failure, suspected infective endocarditis, STEMI, or concurrent pulmonary embolism * A person who is not a member or beneficiary of a social security system * Person deprived of liberty * Person subject to a legal protection measure (curatorship, guardianship) * Person subject to a legal protection measure * Pregnant, parturient or breastfeeding woman
Where this trial is running
Dijon
- Chu Dijon Bourgogne — Dijon, France (Recruiting)
Study contacts
- Study coordinator: Yannick BEJOT
- Email: yannick.bejot@chu-dijon.fr
- Phone: 0380293753
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.